A day after Merck & Co (NYSE: MRK) pulled the plug on its Phase III verubecestat program, alarm bells started ringing over news that Biogen (Nasdaq: BIIB) is adjusting its aducanumab trial, adding over 500 more patients.
While the East Coast, USA-based biotech is yet to see any data from the blinded study, analysts interpreted the move as indicating reduced confidence in the trial design.
Chief medical officer Al Sandrock explained: “We did see more variability on the primary endpoint than assumed when we did the original sample size estimations.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze